NASDAQ:MTP Biodexa Pharmaceuticals (MTP) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free MTP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.29▼$3.2252-Week Range N/AVolume164,300 shsAverage Volume57,354 shsMarket Capitalization$6.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biodexa Pharmaceuticals alerts: Email Address Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. About Biodexa Pharmaceuticals Stock (NASDAQ:MTP)Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Read More Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. MTP Stock News HeadlinesMarch 28, 2024 | benzinga.comExtend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows PotentialMarch 28, 2024 | investorplace.comWhy Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?April 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? February 23, 2024 | msn.comBiodex stock slides 7% amid data for two drug studiesFebruary 13, 2024 | msn.comWhy Is Brain Cancer Focused-Biodexa Pharmaceuticals Stock Trading Higher Today?December 19, 2023 | msn.comCrude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares PlungeDecember 19, 2023 | tmcnet.comBiodexa Announces Pricing of $5.2 Million Underwritten Public OfferingJuly 8, 2023 | benzinga.comBiodexa Pharmaceuticals PLC Announces Results Of Appeal Of Delisting DeterminationApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 25, 2023 | seekingalpha.comBDRX Biodexa Pharmaceuticals PlcApril 4, 2023 | finance.yahoo.comBiodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of EquityMarch 28, 2023 | investorplace.comWhy Is Midatech Pharma (BDRX) Stock Up 64% Today?February 9, 2023 | finance.yahoo.comMidatech Pharma PLC Announces Private Placement Raising US $6.0 millionJanuary 23, 2023 | financialpost.comBioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plcJanuary 12, 2023 | finance.yahoo.comMidatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 StudyJanuary 3, 2023 | finance.yahoo.comBIOAF: Merger with Midatech PharmaDecember 13, 2022 | finance.yahoo.comMidatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies IncDecember 13, 2022 | finance.yahoo.comBioasis Technologies Inc. Announces Merger with Midatech Pharma plcOctober 11, 2022 | seekingalpha.comMTP Midatech Pharma plcSeptember 14, 2022 | marketwatch.comMidatech Pharma Will Need Extra Financing in 1Q 2023; Mulling OptionsSeptember 14, 2022 | finance.yahoo.comMidatech Pharma PLC Announces ADR Ratio ChangeAugust 3, 2022 | thestreet.comMidatech Pharma PLC NewsJune 21, 2022 | finance.yahoo.comMidatech Pharma PLC Announces MTX110 Development for the Treatment of GliomaJune 10, 2022 | yahoo.comMidatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022June 7, 2022 | uk.investing.comMidatech Pharma: MTX110’s Path To Market Fast-Tracked In RGBMJune 1, 2022 | seekingalpha.comMidatech Pharma climbs on FDA’s Fast Track Designation for brain tumor candidateJune 1, 2022 | finance.yahoo.comMidatech's investigational glioblastoma treatment gets Fast Track statusSee More Headlines Receive MTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MTP CUSIPN/A CIK1643918 Webwww.midatechpharma.com Phone441235888300FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$800,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$5.67 per share Price / BookN/AMiscellaneous Outstanding Shares21,670,000Free Float21,595,000Market Cap$6.18 million OptionableNot Optionable Beta2.29 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesStephen Anthony StampChief Executive Officer, CFO, Secretary & DirectorDmitry ZamoryakhinChief Scientific OfficerDan PalmerVice President-TechnologySteve EllulVice President-Business DevelopmentFiona SharpGroup Financial ControllerKey CompetitorsXenetic BiosciencesNASDAQ:XBIOFirst Wave BioPharmaNASDAQ:FWBICadrenal TherapeuticsNASDAQ:CVKDAinosNASDAQ:AIMDProtagenic TherapeuticsNASDAQ:PTIXView All Competitors MTP Stock Analysis - Frequently Asked Questions When did Biodexa Pharmaceuticals' stock split? Shares of Biodexa Pharmaceuticals reverse split before market open on Monday, March 27th 2023. The 1-4 reverse split was announced on Monday, March 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Biodexa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biodexa Pharmaceuticals investors own include CRISPR Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), Plug Power (PLUG), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE). This page (NASDAQ:MTP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
